1 | 13 valent conjugated pneumococcal vaccine | - | - | - | - | 1件: 265 265 |
2 | 150 mg GSK1265744B | - | - | - | - | 1件: 265 265 |
3 | 300mg Gemcabene | 1件: Gemcabene Gemcabene | - | - | - | 1件: 265 265 |
4 | 3TC | - | - | - | - | 2件: 265 265, 325 |
5 | 600mg Gemcabene | 1件: Gemcabene Gemcabene | - | - | - | 1件: 265 265 |
6 | Abacavir | 1件: Abacavir Abacavir | 2件: D00891
D00891
,
D07057
| - | - | 4件: 2 2, 135, 265, 325 |
7 | Abacavir 300mg twice daily | 1件: Abacavir Abacavir | 2件: D00891
D00891
,
D07057
| - | - | 1件: 265 265 |
8 | Abacavir sulfate | 2件: Abacavir Abacavir, Sulfate ion | 2件: D00891
D00891
,
D07057
| - | - | 1件: 265 265 |
9 | Abacavir sulfate, Lamivudine and Zidovudine | 4件: Abacavir Abacavir, Lamivudine, Sulfate ion, Zidovudine | 4件: D00353
D00353
,
D00413
,
D00891
,
D07057
| - | - | 1件: 265 265 |
10 | ABC | - | - | - | - | 2件: 265 265, 325 |
11 | Acetate | 1件: Acetate Acetate | - | - | - | 43件: 1 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299 |
12 | ACETYL- L- CARNITINE | 1件: Levocarnitine Levocarnitine | 3件: D02030
D02030
,
D02176
,
D04713
| - | - | 1件: 265 265 |
13 | Acetylcarnitine | 1件: Acetylcarnitine Acetylcarnitine | - | - | - | 2件: 2 2, 265 |
14 | Acipimox | 1件: Acipimox Acipimox | 1件: D07190
D07190
| - | - | 2件: 78 78, 265 |
15 | AKCEA-ANGPTL3-LRX | - | - | - | - | 2件: 79 79, 265 |
16 | Amprenavir | 1件: Amprenavir Amprenavir | 1件: D00894
D00894
| - | - | 1件: 265 265 |
17 | Antiretroviral/Anti HIV | - | - | - | - | 1件: 265 265 |
18 | Aramchol | 1件: Aramchol Aramchol | - | - | - | 1件: 265 265 |
19 | Atazanavir | 1件: Atazanavir Atazanavir | 2件: D01276
D01276
,
D07471
| - | - | 1件: 265 265 |
20 | Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs) | 2件: Atazanavir Atazanavir, Ritonavir | 3件: D00427
D00427
,
D01276
,
D07471
| - | - | 1件: 265 265 |
21 | Atazanavir (Reyataz) | 1件: Atazanavir Atazanavir | 2件: D01276
D01276
,
D07471
| - | - | 1件: 265 265 |
22 | Atazanavir/Ritonavir | 2件: Atazanavir Atazanavir, Ritonavir | 3件: D00427
D00427
,
D01276
,
D07471
| - | - | 1件: 265 265 |
23 | Atorvastatin | 1件: Atorvastatin Atorvastatin | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 18件: 13 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299 |
24 | Atorvastatin Calcium | 2件: Atorvastatin Atorvastatin, Calcium | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 2件: 97 97, 265 |
25 | ATV | - | - | - | - | 1件: 265 265 |
26 | Avandia administration for 6-12 weeks | - | - | - | - | 1件: 265 265 |
27 | AZT | - | - | - | - | 3件: 94 94, 265, 325 |
28 | AZT/3TC | - | - | - | - | 1件: 265 265 |
29 | Baricitinib | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 13件: 41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 |
30 | Behavioral: 60-minutes of steady state exercise | - | - | - | - | 1件: 265 265 |
31 | Behavioral: Diet | - | - | - | - | 1件: 265 265 |
32 | Behavioral: Exercise | - | - | - | - | 3件: 6 6, 265, 299 |
33 | Behavioral: Exercise Training | - | - | - | - | 1件: 265 265 |
34 | Berberine | 1件: Berberine Berberine | - | - | - | 2件: 97 97, 265 |
35 | BMS-232632 | - | - | - | - | 1件: 265 265 |
36 | Caffeine | 1件: Caffeine Caffeine | 2件: D00528
D00528
,
D01453
| 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
37 | Calcium | 1件: Calcium Calcium | - | - | - | 30件: 3 3, 6, 13, 15, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 186, 214, 215, 222, 224, 235, 256, 265, 274, 298, 299 |
38 | Carnitine | 1件: Levocarnitine Levocarnitine | 3件: D02030
D02030
,
D02176
,
D04713
| - | - | 9件: 5 5, 13, 58, 86, 96, 97, 265, 298, 316 |
39 | CD | - | - | - | - | 7件: 6 6, 13, 46, 51, 96, 97, 265 |
40 | CD-4 guided therapy interruption | - | - | - | - | 1件: 265 265 |
41 | Cholic Acid | 1件: Cholic Acid Cholic Acid | 1件: D10699
D10699
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 4件: 20 20, 234, 265, 310 |
42 | CoFactor | - | - | - | - | 3件: 6 6, 265, 288 |
43 | Cofactor supplementation (thiamine, riboflavin, L-carnitine) | 3件: Levocarnitine Levocarnitine, Riboflavin, Thiamine | 7件: D00050
D00050
,
D01622
,
D01913
,
D02030
,
D02176
,
D04713
,
D08580
| - | - | 1件: 265 265 |
44 | COMBIVIR | 1件: Zidovudine Zidovudine | 1件: D00413
D00413
| - | - | 1件: 265 265 |
45 | Combivir (zidovudine [AZT] / lamivudine [3TC]) | 2件: Lamivudine Lamivudine, Zidovudine | 2件: D00353
D00353
,
D00413
| - | - | 1件: 265 265 |
46 | Continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) | - | - | - | - | 1件: 265 265 |
47 | Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 45件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 |
48 | Didanosine | 1件: Didanosine Didanosine | 1件: D00296
D00296
| - | - | 2件: 25 25, 265 |
49 | Different HAART regimens | - | - | - | - | 1件: 265 265 |
50 | DIOSMIN | 1件: Diosmin Diosmin | 1件: D07858
D07858
| - | - | 1件: 265 265 |
51 | Diosminex, 500 mg, tabletki powlekane | - | - | - | - | 1件: 265 265 |
52 | Dolutegravir | 1件: Dolutegravir Dolutegravir | 1件: D10066
D10066
| - | - | 2件: 2 2, 265 |
53 | Dolutegravir / Lamivudine Oral Tablet | 2件: Dolutegravir Dolutegravir, Lamivudine | 2件: D00353
D00353
,
D10066
| - | - | 1件: 265 265 |
54 | Dolutegravir 50 MG | 1件: Dolutegravir Dolutegravir | 1件: D10066
D10066
| - | - | 1件: 265 265 |
55 | Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO] | 2件: Dolutegravir Dolutegravir, Lamivudine | 2件: D00353
D00353
,
D10066
| - | - | 1件: 265 265 |
56 | Doravirine | 1件: Doravirine Doravirine | 1件: D10624
D10624
| - | - | 1件: 265 265 |
57 | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] | 3件: Lamivudine Lamivudine, Tenofovir, Tenofovir disoproxil | 3件: D00353
D00353
,
D01982
,
D06074
| - | - | 1件: 265 265 |
58 | Efavirenz | 1件: Efavirenz Efavirenz | 1件: D00896
D00896
| - | - | 1件: 265 265 |
59 | Efavirenz (EFV) | 1件: Efavirenz Efavirenz | 1件: D00896
D00896
| - | - | 1件: 265 265 |
60 | Emtricitabine | 1件: Emtricitabine Emtricitabine | 1件: D01199
D01199
| - | - | 4件: 25 25, 93, 265, 325 |
61 | Emtricitabine/tenofovir | 2件: Emtricitabine Emtricitabine, Tenofovir | 2件: D01199
D01199
,
D06074
| - | - | 1件: 265 265 |
62 | Enfuvirtide | 1件: Enfuvirtide Enfuvirtide | 1件: D02499
D02499
| - | - | 2件: 25 25, 265 |
63 | Enfuvirtide (T20) | 1件: Enfuvirtide Enfuvirtide | 1件: D02499
D02499
| - | - | 1件: 265 265 |
64 | Fenofibrate | 1件: Fenofibrate Fenofibrate | 1件: D00565
D00565
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 5件: 8 8, 79, 93, 94, 265 |
65 | Gemcabene | 1件: Gemcabene Gemcabene | - | - | - | 2件: 79 79, 265 |
66 | Genetic: Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene | - | - | - | - | 1件: 265 265 |
67 | Genotropin (human recombinant Growth hormone) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 265 265 |
68 | Glycerine | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 1件: 265 265 |
69 | Growth hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 13件: 2 2, 13, 19, 46, 78, 96, 107, 187, 191, 193, 195, 265, 299 |
70 | Growth Hormone Releasing Hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 265 265 |
71 | GSK1265744B (sodium salt) containing 14C-GSK1265744B | - | - | - | - | 1件: 265 265 |
72 | High-carbohdyrate breakfast | - | - | - | - | 1件: 265 265 |
73 | High-dose REGN4461 | - | - | - | - | 1件: 265 265 |
74 | Hu Leptin (A-100) | 1件: Leptin Leptin | - | - | - | 1件: 265 265 |
75 | Human Growth Hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 4件: 78 78, 187, 193, 265 |
76 | Human recombinant leptin (metreleptin) | 2件: Leptin Leptin, Metreleptin | 1件: D05014
D05014
| 1件: LEPR LEPR 💬 | 6件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease 💬 | 1件: 265 265 |
77 | Indinavir | 1件: Indinavir Indinavir | 3件: D00897
D00897
,
D02861
,
D03833
| - | - | 1件: 265 265 |
78 | ISIS 304801 | - | - | - | - | 1件: 265 265 |
79 | Kaletra (lopinavir [LPVr]) | 1件: Lopinavir Lopinavir | 1件: D01425
D01425
| - | - | 1件: 265 265 |
80 | L-Carnitine | 1件: Levocarnitine Levocarnitine | 3件: D02030
D02030
,
D02176
,
D04713
| - | - | 7件: 13 13, 86, 96, 97, 265, 298, 316 |
81 | L-Lactic acid | 2件: L-Lactic acid L-Lactic acid, Lactic acid | 1件: D00111
D00111
| - | - | 1件: 265 265 |
82 | Lactic acid | 1件: Lactic acid Lactic acid | 1件: D00111
D00111
| - | - | 2件: 265 265, 299 |
83 | Lamivudine | 1件: Lamivudine Lamivudine | 1件: D00353
D00353
| - | - | 7件: 2 2, 26, 42, 46, 135, 265, 325 |
84 | Lamivudine/Zidovudine | 2件: Lamivudine Lamivudine, Zidovudine | 2件: D00353
D00353
,
D00413
| - | - | 1件: 265 265 |
85 | Leptin | 1件: Leptin Leptin | - | - | - | 2件: 6 6, 265 |
86 | Lopinavir | 1件: Lopinavir Lopinavir | 1件: D01425
D01425
| - | - | 1件: 265 265 |
87 | Lopinavir/Ritonavir | 2件: Lopinavir Lopinavir, Ritonavir | 2件: D00427
D00427
,
D01425
| - | - | 1件: 265 265 |
88 | Lopinavir/ritonavir + nevirapine | 3件: Lopinavir Lopinavir, Nevirapine, Ritonavir | 3件: D00427
D00427
,
D00435
,
D01425
| - | - | 1件: 265 265 |
89 | Lopinavir/ritonavir + zidovudine + lamivudine | 4件: Lamivudine Lamivudine, Lopinavir, Ritonavir, Zidovudine | 4件: D00353
D00353
,
D00413
,
D00427
,
D01425
| - | - | 1件: 265 265 |
90 | Low-Dose REGN4461 | - | - | - | - | 1件: 265 265 |
91 | Mecasermin | 1件: Mecasermin Mecasermin | 2件: D03297
D03297
,
D04870
| 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 5件: 78 78, 96, 168, 265, 299 |
92 | Metformin | 1件: Metformin Metformin | 2件: D00944
D00944
,
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
93 | METFORMIN HYDROCHLORIDE | 1件: Metformin Metformin | 2件: D00944
D00944
,
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 5件: 81 81, 158, 265, 299, 301 |
94 | METRELEPTIN | 1件: Metreleptin Metreleptin | 1件: D05014
D05014
| 1件: LEPR LEPR 💬 | 6件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease 💬 | 1件: 265 265 |
95 | Metrelpetin | - | - | - | - | 1件: 265 265 |
96 | Monotherapy (Lopinavir/ritonavir) | 2件: Lopinavir Lopinavir, Ritonavir | 2件: D00427
D00427
,
D01425
| - | - | 1件: 265 265 |
97 | Monotherapy (Lopinavir/ritonavir) + ABC/3TC | 2件: Lopinavir Lopinavir, Ritonavir | 2件: D00427
D00427
,
D01425
| - | - | 1件: 265 265 |
98 | Myalept | 1件: Metreleptin Metreleptin | 1件: D05014
D05014
| 1件: LEPR LEPR 💬 | 6件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease 💬 | 1件: 265 265 |
99 | N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate | 2件: Acetate Acetate, Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 265 265 |
100 | Nelfinavir | 1件: Nelfinavir Nelfinavir | 2件: D00899
D00899
,
D08259
| - | - | 3件: 49 49, 265, 331 |
101 | Nelfinavir mesylate | 1件: Nelfinavir Nelfinavir | 2件: D00899
D00899
,
D08259
| - | - | 1件: 265 265 |
102 | Nevirapine | 1件: Nevirapine Nevirapine | 1件: D00435
D00435
| - | - | 1件: 265 265 |
103 | Niacin | 1件: Niacin Niacin | 1件: D00049
D00049
| - | - | 3件: 6 6, 78, 265 |
104 | Non-nucleoside reverse transcriptase inhibitors | - | - | - | - | 1件: 265 265 |
105 | Norvir | 1件: Ritonavir Ritonavir | 1件: D00427
D00427
| - | - | 2件: 265 265, 299 |
106 | NucleomaxX | - | - | - | - | 1件: 265 265 |
107 | Nucleoside analogue sparing HAART regimen | - | - | - | - | 1件: 265 265 |
108 | Nucleoside reverse transcriptase inhibitors | - | - | - | - | 1件: 265 265 |
109 | Obeticholic Acid | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 3件: 93 93, 265, 296 |
110 | Other: Glycerine gel | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 1件: 265 265 |
111 | Other: Observation | - | - | - | - | 1件: 265 265 |
112 | Perform blood cells and fibroblasts biochemical and immuno-labeled investigations | - | - | - | - | 1件: 265 265 |
113 | Pioglitazone | 1件: Pioglitazone Pioglitazone | 2件: D00945
D00945
,
D08378
| 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
114 | Pioglitazone or metformin | 2件: Metformin Metformin, Pioglitazone | 4件: D00944
D00944
,
D00945
,
D04966
,
D08378
| 3件: PPARG PPARG, PRKAA1, PRKAA2 💬 | 27件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Huntington disease, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Osteoclast differentiation, Oxytocin signaling pathway, PI3K-Akt signaling pathway, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Tight junction, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 265 265 |
115 | Pneumococcal polysaccharide vaccine 23 valent | - | - | - | - | 1件: 265 265 |
116 | POLY-L-LACTIC ACID | 3件: L-Lactic acid L-Lactic acid, Lactic acid, Poly(lactic acid) | 1件: D00111
D00111
| - | - | 1件: 265 265 |
117 | Pravastatin | 1件: Pravastatin Pravastatin | 2件: D00893
D00893
,
D08410
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 9件: 13 13, 46, 49, 67, 79, 96, 164, 265, 333 |
118 | Pravastatin sodium | 1件: Pravastatin Pravastatin | 2件: D00893
D00893
,
D08410
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 265 265 |
119 | Prevenar13 | - | - | - | - | 2件: 19 19, 265 |
120 | Protease inhibitor | - | - | - | - | 1件: 265 265 |
121 | Protease inhibitors | - | - | - | - | 1件: 265 265 |
122 | R-metHuLeptin | 1件: Metreleptin Metreleptin | 1件: D05014
D05014
| 1件: LEPR LEPR 💬 | 6件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease 💬 | 1件: 265 265 |
123 | Raltegravir | 1件: Raltegravir Raltegravir | 1件: D06676
D06676
| - | - | 4件: 13 13, 26, 93, 265 |
124 | RECOMBINANT HUMAN GROWTH HORMONE | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 78 78, 193, 265 |
125 | Recombinant human growth hormone + rosiglitazone | 2件: Rosiglitazone Rosiglitazone, Somatotropin | 3件: D00596
D00596
,
D02691
,
D08491
| 2件: GHR GHR, PPARG 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, Huntington disease, JAK-STAT signaling pathway, Lipid and atherosclerosis, Longevity regulating pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 265 265 |
126 | REGN4461 | - | - | - | - | 1件: 265 265 |
127 | Reyataz | 1件: Atazanavir Atazanavir | 2件: D01276
D01276
,
D07471
| - | - | 1件: 265 265 |
128 | REYATAZ 150MG 60 CPS BL | 1件: Atazanavir Atazanavir | 2件: D01276
D01276
,
D07471
| - | - | 1件: 265 265 |
129 | Riboflavin | 1件: Riboflavin Riboflavin | 3件: D00050
D00050
,
D01622
,
D01913
| - | - | 8件: 13 13, 38, 46, 96, 97, 162, 168, 265 |
130 | Ritonavir | 1件: Ritonavir Ritonavir | 1件: D00427
D00427
| - | - | 3件: 2 2, 86, 265 |
131 | Ritonavir (Norvir) | 1件: Ritonavir Ritonavir | 1件: D00427
D00427
| - | - | 1件: 265 265 |
132 | Rosiglitazone | 1件: Rosiglitazone Rosiglitazone | 2件: D00596
D00596
,
D08491
| 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 5件: 46 46, 75, 97, 222, 265 |
133 | Rosiglitazone maleate | 1件: Rosiglitazone Rosiglitazone | 2件: D00596
D00596
,
D08491
| 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 3件: 46 46, 75, 265 |
134 | RTV | - | - | - | - | 1件: 265 265 |
135 | Saquinavir | 1件: Saquinavir Saquinavir | 2件: D00429
D00429
,
D01160
| - | - | 2件: 86 86, 265 |
136 | Serostim®[somatropin (rDNA origin) for injection] | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 265 265 |
137 | Setmelanotide | 1件: Setmelanotide Setmelanotide | 1件: D11927
D11927
| 1件: MC4R MC4R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 202 202, 265 |
138 | Simvastatin | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 21件: 6 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 |
139 | Somatropin | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 19件: 2 2, 3, 19, 46, 65, 74, 75, 78, 96, 107, 113, 187, 193, 195, 238, 265, 274, 276, 299 |
140 | ST200 | - | - | - | - | 1件: 265 265 |
141 | Standard continuous antiretroviral therapy | - | - | - | - | 1件: 265 265 |
142 | Stavudine | 1件: Stavudine Stavudine | 1件: D00445
D00445
| - | - | 1件: 265 265 |
143 | Sulfate | 1件: Sulfate ion Sulfate ion | - | - | - | 27件: 2 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 218, 222, 226, 265, 296, 297, 299 |
144 | SUSTIVA | 1件: Efavirenz Efavirenz | 1件: D00896
D00896
| - | - | 1件: 265 265 |
145 | TAT4 Gel concentration A | - | - | - | - | 1件: 265 265 |
146 | TAT4 Gel concentration B | - | - | - | - | 1件: 265 265 |
147 | Tenofovir | 1件: Tenofovir disoproxil Tenofovir disoproxil | 1件: D01982
D01982
| - | - | 6件: 2 2, 13, 25, 93, 265, 325 |
148 | Tenofovir DF | 1件: Tenofovir Tenofovir | 1件: D06074
D06074
| - | - | 1件: 265 265 |
149 | Tenofovir disoproxil | 2件: Tenofovir Tenofovir, Tenofovir disoproxil | 2件: D01982
D01982
,
D06074
| - | - | 2件: 93 93, 265 |
150 | Tenofovir Disoproxil Fumarate | 2件: Tenofovir Tenofovir, Tenofovir disoproxil | 2件: D01982
D01982
,
D06074
| - | - | 1件: 265 265 |
151 | Tesamorelin | 1件: Tesamorelin Tesamorelin | 1件: D06655
D06655
| 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 2件: 78 78, 265 |
152 | Tesamorelin (Egrifta) | 1件: Tesamorelin Tesamorelin | 1件: D06655
D06655
| 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 1件: 265 265 |
153 | Testosterone | 1件: Testosterone Testosterone | 6件: D00075
D00075
,
D00957
,
D00958
,
D00959
,
D06085
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 9件: 1 1, 2, 3, 13, 60, 76, 78, 113, 265 |
154 | Testosterone injection | 1件: Testosterone Testosterone | 6件: D00075
D00075
,
D00957
,
D00958
,
D00959
,
D06085
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 265 265 |
155 | TH9507 | - | - | - | - | 1件: 265 265 |
156 | Thiamine | 1件: Thiamine Thiamine | 1件: D08580
D08580
| - | - | 4件: 8 8, 13, 93, 265 |
157 | Tipranavir | 1件: Tipranavir Tipranavir | 2件: D03843
D03843
,
D08605
| - | - | 1件: 265 265 |
158 | Total Dietary Replacement | - | - | - | - | 1件: 265 265 |
159 | TRUVADA | 1件: Emtricitabine Emtricitabine | 1件: D01199
D01199
| - | - | 1件: 265 265 |
160 | Use of lipid-lowering drugs. | - | - | - | - | 1件: 265 265 |
161 | Venus Versa | - | - | - | - | 1件: 265 265 |
162 | Viral load driven treatment interruption | - | - | - | - | 1件: 265 265 |
163 | Volanesorsen | 1件: Volanesorsen Volanesorsen | 1件: D11648
D11648
| 1件: APOC3 APOC3 💬 | 2件: Cholesterol metabolism Cholesterol metabolism, PPAR signaling pathway 💬 | 1件: 265 265 |
164 | VOLANESORSEN SODIUM, ApoC-III Antisense Oligonucleotide | 1件: Volanesorsen Volanesorsen | 1件: D11648
D11648
| 1件: APOC3 APOC3 💬 | 2件: Cholesterol metabolism Cholesterol metabolism, PPAR signaling pathway 💬 | 1件: 265 265 |
165 | Zidovudine | 1件: Zidovudine Zidovudine | 1件: D00413
D00413
| - | - | 6件: 25 25, 26, 135, 265, 325, 331 |